Back to Search Start Over

Targeting senescence as an anticancer therapy

Authors :
Laura Bousset
Jesús Gil
Source :
Molecular Oncology. 16:3855-3880
Publication Year :
2022
Publisher :
Wiley, 2022.

Abstract

Cellular senescence is a stress response elicited by different molecular insults. Senescence results in cell cycle exit and is characterised by multiple phenotypic changes such as the production of a bioactive secretome. Senescent cells accumulate during ageing and are present in cancerous and fibrotic lesions. Drugs that selectively kill senescent cells (senolytics) have shown great promise for the treatment of age-related diseases. Senescence plays paradoxical roles in cancer. Induction of senescence limits cancer progression and contributes to therapy success, but lingering senescent cells fuel progression, recurrence, and metastasis. In this review, we describe the intricate relation between senescence and cancer. Moreover, we enumerate how current anti-cancer therapies induce senescence in tumour cells and how senolytic agents could be deployed to complement anticancer therapies. "One-two punch" therapies aim to first induce senescence in the tumour followed by senolytic treatment to target newly exposed vulnerabilities in senescent tumour cells. "One-two punch" represents an emerging and promising new strategy in cancer treatment. Future challenges of "one -two punch" approaches include how to best monitor senescence in cancer patients to effectively survey their efficacy.

Details

ISSN :
18780261 and 15747891
Volume :
16
Database :
OpenAIRE
Journal :
Molecular Oncology
Accession number :
edsair.doi.dedup.....b5a587af44527b37104f1a033d661244